Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2022

01-12-2022 | Alzheimer's Disease | Research

Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people

Authors: Christopher Clark, Jonas Richiardi, Bénédicte Maréchal, Gene L. Bowman, Loïc Dayon, Julius Popp

Published in: Journal of Neuroinflammation | Issue 1/2022

Login to get access

Abstract

Background

Neuroinflammation may contribute to psychiatric symptoms in older people, in particular in the context of Alzheimer’s disease (AD). We sought to identify systemic and central nervous system (CNS) inflammatory alterations associated with neuropsychiatric symptoms (NPS); and to investigate their relationships with AD pathology and clinical disease progression.

Methods

We quantified a panel of 38 neuroinflammation and vascular injury markers in paired serum and cerebrospinal fluid (CSF) samples in a cohort of cognitively normal and impaired older subjects. We performed neuropsychiatric and cognitive evaluations and measured CSF biomarkers of AD pathology. Multivariate analysis determined serum and CSF neuroinflammatory alterations associated with NPS, considering cognitive status, AD pathology, and cognitive decline at follow-up visits.

Results

NPS were associated with distinct inflammatory profiles in serum, involving eotaxin-3, interleukin (IL)-6 and C-reactive protein (CRP); and in CSF, including soluble intracellular cell adhesion molecule-1 (sICAM-1), IL-8, 10-kDa interferon-γ-induced protein, and CRP. AD pathology interacted with CSF sICAM-1 in association with NPS. Presenting NPS was associated with subsequent cognitive decline which was mediated by CSF sICAM-1.

Conclusions

Distinct systemic and CNS inflammatory processes are involved in the pathophysiology of NPS in older people. Neuroinflammation may explain the link between NPS and more rapid clinical disease progression.
Appendix
Available only for authorised users
Literature
1.
Youn JC, Lee DY, Jhoo JH, Kim KW, Choo IH, Woo JI. Prevalence of neuropsychiatric syndromes in Alzheimer’s disease (AD). Arch Gerontol Geriatr. 2011;52(3):258–63.PubMedCrossRef
2.
Rozum WJ, Cooley B, Vernon E, Matyi J, Tschanz JT. Neuropsychiatric symptoms in severe dementia: associations with specific cognitive domains the Cache County Dementia Progression Study. Int J Geriatr Psychiatry. 2019;34:1087–94.PubMedPubMedCentralCrossRef
3.
Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimer’s Dement (Amsterdam, Netherlands). 2019;11:333–9.CrossRef
4.
Liew TM. Neuropsychiatric symptoms in early stage of Alzheimer’s and non-Alzheimer’s dementia, and the risk of progression to severe dementia. Age Ageing. 2021;50(5):1709–18.PubMedPubMedCentralCrossRef
5.
Burhanullah MH, Tschanz JT, Peters ME, Leoutsakos JM, Matyi J, Lyketsos CG, et al. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: the cache county study. Am J Geriatr Psychiatry. 2019;28:64–71.PubMedPubMedCentralCrossRef
6.
Missotten P, Squelard G, Ylieff M, Di Notte D, Paquay L, de Lepeleire J, et al. Relationship between quality of life and cognitive decline in dementia. Dement Geriatr Cogn Disord. 2008;25(6):564–72.PubMedCrossRef
7.
Vetrano DL, Rizzuto D, Calderon-Larranaga A, Onder G, Welmer AK, Bernabei R, et al. Trajectories of functional decline in older adults with neuropsychiatric and cardiovascular multimorbidity: a Swedish cohort study. PLoS Med. 2018;15(3):e1002503.PubMedPubMedCentralCrossRef
8.
Dantzer R. Cytokine, sickness behavior, and depression. Immunol Allergy Clin N Am. 2009;29(2):247–64.CrossRef
9.
Combrinck MI, Perry VH, Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience. 2002;112(1):7–11.PubMedCrossRef
10.
Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25(40):9275–84.PubMedPubMedCentralCrossRef
11.
Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry. 2009;65(4):304–12.PubMedPubMedCentralCrossRef
12.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46–56.PubMedPubMedCentralCrossRef
13.
Rengasamy M, Zhong Y, Marsland A, Chen K, Douaihy A, Brent D, et al. Signaling networks in inflammatory pathways and risk for suicidal behavior. Brain Behav Immunity Health. 2020;7:100122.CrossRef
14.
Irving P, Barrett K, Nijher M, Lusignan SD. Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study. Evid Based Ment Health. 2021;24:102–9.PubMedCentralCrossRef
15.
Obermanns J, Krawczyk E, Juckel G, Emons B. Analysis of cytokine levels, T regulatory cells and serotonin content in patients with a depressive disorder. Eur J Neurosci. 2021;53:3476–89.PubMedCrossRef
16.
Capuron L, Castanon N. Role of inflammation in the development of neuropsychiatric symptom domains: evidence and mechanisms. Curr Top Behav Neurosci. 2017;31:31–44.PubMedCrossRef
17.
Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10):768–74.PubMedPubMedCentralCrossRef
18.
Popp J. Delirium and cognitive decline: more than a coincidence. Curr Opin Neurol. 2013;26(6):634–9.PubMedCrossRef
19.
Popp J, Oikonomidi A, Tautvydaite D, Dayon L, Bacher M, Migliavacca E, et al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun. 2017;62:203–11.PubMedCrossRef
20.
Amin J, Boche D, Clough Z, Teeling J, Williams A, Gao Y, et al. Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer’s disease: an observational clinical study. J Neurol Neurosurg Psychiatry. 2020;91(11):1219–26.PubMedCrossRef
21.
Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ, Barkhof F, et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimer’s Dement. 2019;15:776–87.CrossRef
22.
Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J Neuroimmunol. 2000;103(1):97–102.PubMedCrossRef
23.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.PubMedCrossRef
24.
Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer’s pathology in MCI and mild dementia. Exp Gerontol. 2017;100:45–53.PubMedCrossRef
25.
Buschke H, Sliwinski MJ, Kuslansky G, Lipton RB. Diagnosis of early dementia by the Double Memory Test: encoding specificity improves diagnostic sensitivity and specificity. Neurology. 1997;48(4):989–97.PubMedCrossRef
26.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643–62.CrossRef
27.
Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8(3):271–6.CrossRef
28.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9(3 Part 1):179–86.PubMedCrossRef
29.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.PubMedCrossRef
30.
Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer’s Dement. 2018;14(12):1640–50.CrossRef
31.
Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol. 2017;17(1):49–59.PubMedCrossRef
32.
Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359–62.PubMedCrossRef
33.
Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91(9):e867–77.PubMedPubMedCentralCrossRef
34.
Rivera-Rivera Y, García Y, Toro V, Cappas N, López P, Yamamura Y, et al. Depression correlates with increased plasma levels of inflammatory cytokines and a dysregulated oxidant/antioxidant balance in HIV-1-infected subjects undergoing antiretroviral therapy. J Clin Cell Immunol. 2014;5(6):1000276.PubMedPubMedCentral
35.
Janelidze S, Suchankova P, Ekman A, Erhardt S, Sellgren C, Samuelsson M, et al. Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatr Scand. 2015;131(4):269–78.PubMedCrossRef
36.
Sajjad MU, Blennow K, Knapskog AB, Idland A-V, Chaudhry FA, Wyller TB, et al. Cerebrospinal fluid levels of interleukin-8 in delirium, dementia, and cognitively healthy patients. J Alzheimers Dis. 2020;73(4):1363–72.PubMedCrossRef
37.
Capuron L, Schroecksnadel S, Féart C, Aubert A, Higueret D, Barberger-Gateau P, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70(2):175–82.PubMedCrossRef
38.
Bíró A, Rovó Z, Papp D, Cervenak L, Varga L, Füst G, et al. Studies on the interactions between C-reactive protein and complement proteins. Immunology. 2007;121(1):40–50.PubMedPubMedCentralCrossRef
39.
Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011;77(3):212–8.PubMedPubMedCentralCrossRef
40.
van den Biggelaar AHJ, Gussekloo J, de Craen AJM, Frölich M, Stek ML, van der Mast RC, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol. 2007;42(7):693–701.PubMedCrossRef
41.
Han JH, Wong KS, Wang YY, Fu JH, Ding D, Hong Z. Plasma level of sICAM-1 is associated with the extent of white matter lesion among asymptomatic elderly subjects. Clin Neurol Neurosurg. 2009;111(10):847–51.PubMedCrossRef
42.
Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology. 2012;78(10):720–7.PubMedCrossRef
43.
Gongvatana A, Correia S, Dunsiger S, Gauthier L, Devlin KN, Ross S, et al. Plasma cytokine levels are related to brain volumes in HIV-infected individuals. J Neuroimmune Pharmacol. 2014;9(5):740–50.PubMedPubMedCentralCrossRef
44.
Yousef H, Czupalla CJ, Lee D, Chen MB, Burke AN, Zera KA, et al. Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1. Nat Med. 2019;25(6):988–1000.PubMedPubMedCentralCrossRef
45.
Dayon L, Cominetti O, Wojcik J, Galindo AN, Oikonomidi A, Henry H, et al. Proteomes of paired human cerebrospinal fluid and plasma: relation to blood-brain barrier permeability in older adults. J Proteome Res. 2019;18(3):1162–74.PubMedCrossRef
46.
Miguel-Hidalgo JJ, Nithuairisg S, Stockmeier C, Rajkowska G. Distribution of ICAM-1 immunoreactivity during aging in the human orbitofrontal cortex. Brain Behav Immun. 2007;21(1):100–11.PubMedCrossRef
47.
Closhen D, Bender B, Luhmann HJ, Kuhlmann CR. CRP-induced levels of oxidative stress are higher in brain than aortic endothelial cells. Cytokine. 2010;50(2):117–20.PubMedCrossRef
48.
Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75–83.PubMedCrossRef
49.
Enache D, Pariante CM, Mondelli V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun. 2019;81:24–40.PubMedCrossRef
50.
Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, et al. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry. 2020;25(6):1301–11.PubMedCrossRef
51.
van Dooren FE, Schram MT, Schalkwijk CG, Stehouwer CD, Henry RM, Dagnelie PC, et al. Associations of low grade inflammation and endothelial dysfunction with depression—The Maastricht Study. Brain Behav Immun. 2016;56:390–6.PubMedCrossRef
52.
Barron AM, Tokunaga M, Zhang MR, Ji B, Suhara T, Higuchi M. Assessment of neuroinflammation in a mouse model of obesity and beta-amyloidosis using PET. J Neuroinflamm. 2016;13(1):221.CrossRef
53.
Bartos A, Gregus D, Ibrahim I, Tintera J. Brain volumes and their ratios in Alzheimer s disease on magnetic resonance imaging segmented using Freesurfer 6.0. Psychiatry Res Neuroimaging. 2019;287:70–4.PubMedCrossRef
54.
Boublay N, Schott AM, Krolak-Salmon P. Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer’s disease: a review of 20 years of research. Eur J Neurol. 2016;23(10):1500–9.PubMedCrossRef
55.
Whitwell JL. Progression of atrophy in Alzheimer’s disease and related disorders. Neurotox Res. 2010;18(3–4):339–46.PubMedCrossRef
Metadata
Title
Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people
Authors
Christopher Clark
Jonas Richiardi
Bénédicte Maréchal
Gene L. Bowman
Loïc Dayon
Julius Popp
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2022
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-022-02473-3

Other articles of this Issue 1/2022

Journal of Neuroinflammation 1/2022 Go to the issue

Research

Sublethal enteroviral infection exacerbates disease progression in an ALS mouse model

Research

Adaptation of prelimbic cortex mediated by IL-6/STAT3/Acp5 pathway contributes to the comorbidity of neuropathic pain and depression in rats

Research

Nicotinamide reverses deficits in puberty-born neurons and cognitive function after maternal separation

Research

An overlooked subset of Cx3cr1wt/wt microglia in the Cx3cr1CreER-Eyfp/wt mouse has a repopulation advantage over Cx3cr1CreER-Eyfp/wt microglia following microglial depletion

Research

Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model

Research

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure